Adaptive Biotechnologies
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 18 in the most recent period (2026/Q3).
- Total institutional ownership rose 2.6 percentage points.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 102.60% +2.63pp
- Institutions
- 391 +18
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-06-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 0 buys · 50 sells
| Name | Role | Stake |
|---|---|---|
| Viking Global Investors LP | -- | 18.53% |
| Chad Robins | Chairperson & CEO | 0.94% |
| Harlan Robins | Co-Founder & Former Chief Scientific Officer | 0.50% |
| Susan Bobulsky | Chief Commercial Officer of MRD | 0.24% |
| Julie Rubinstein | President | 0.23% |
| Kyle Piskel | VP, CFO & Principal Accounting Officer | 0.16% |
| Francis Lo | Chief Human Resources Officer | 0.14% |
| Sharon Benzeno | Chief Commercial Officer of Immune Medicine | 0.14% |
| Peter Neupert | Lead Independent Director | 0.08% |
| Katey Owen | Independent Director | 0.04% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-12 | Julie Rubinstein | President | Derivative Exercise and Sale | -35,228 | $12.14–31.22 |
| 2026-11-10 | Chad Robins | Chairperson & CEO | Intent to Sell (Form 144) | -73,221 | $29.94 |
| 2026-11-10 | Susan Bobulsky | Chief Commercial Officer of MRD | Automatic Disposition | -1,875 | $32.00 |
| 2026-11-09 | Julie Rubinstein | President | Derivative Exercise and Sale | -23,762 | $12.14–30.58 |
| 2026-11-08 | Chad Robins | Chairperson & CEO | Other Disposition | -100,000 | -- |
| 2026-11-05 | Julie Rubinstein | President | Derivative Exercise and Sale | -35,643 | $12.14–27.88 |
| 2026-11-02 | Julie Rubinstein | President | Derivative Exercise and Sale | -35,643 | $12.14–27.45 |
| 2026-10-28 | Julie Rubinstein | President | Derivative Exercise and Sale | -35,643 | $12.14–28.90 |
| 2026-10-25 | Julie Rubinstein | President | Derivative Exercise and Sale | -35,643 | $12.14–26.30 |
| 2026-10-20 | Julie Rubinstein | President | Derivative Exercise and Sale | -35,643 | $12.14–25.57 |
| 2026-10-15 | Julie Rubinstein | President | Derivative Exercise and Sale | -35,643 | $12.14–25.82 |
| 2026-10-12 | Julie Rubinstein | President | Derivative Exercise and Sale | -35,643 | $12.14–26.41 |
| 2026-10-07 | Julie Rubinstein | President | Derivative Exercise and Sale | -35,643 | $12.14–30.53 |
| 2026-10-05 | Susan Bobulsky | Chief Commercial Officer of MRD | Automatic Disposition | -6,444 | $30.00 |
| 2026-10-04 | Julie Rubinstein | President | Derivative Exercise and Sale | -35,643 | $12.14–29.67 |
| 2026-09-30 | Julie Rubinstein | President | Intent to Sell (Form 144) | -379,777 | $28.90 |
| 2026-09-30 | Francis Lo | Chief Human Resources Officer | Derivative Exercise and Sale | -26,792 | $3.99–28.61 |
| 2026-09-15 | Francis Lo | Chief Human Resources Officer | Automatic Disposition | -9,846 | $28.02–28.57 |
| 2026-09-15 | Francis Lo | Chief Human Resources Officer | Derivative Exercise and Sale | -105,560 | $3.99–28.02 |
| 2026-09-14 | Susan Bobulsky | Chief Commercial Officer of MRD | Automatic Disposition | -1,195 | $27.00 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:38 · For reference only, not investment advice and not tailored to your situation.
Adaptive Biotechnologies discussion 0 comments